Clinical Trials Browser

Has results × CB-839 × Clear all

NCT02861300 2024-12-19

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

Phase 1/2 Completed

50 enrolled 16 charts

Gastrointestinal

Colonic Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Rectal Neoplasms, Colorectal Neoplasms

NCT03263429 2024-08-30

Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer

Phase 1/2 Completed

29 enrolled 17 charts

Gastrointestinal

Colorectal Neoplasms

NCT03047993 2024-05-14

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

Phase 1/2 Completed

28 enrolled 8 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT03428217 2023-03-20

CANTATA

Phase 2 Completed

444 enrolled 15 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03057600 2022-09-28

Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)

Phase 2 Completed

52 enrolled 16 charts

Triple Negative Breast Neoplasms

NCT03163667 2022-09-15

ENTRATA

Phase 2 Completed

69 enrolled 12 charts

Carcinoma, Renal Cell

NCT03875313 2022-02-17

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Phase 1/2 Terminated

33 enrolled 14 charts

BreastGastrointestinalGenitourinary

Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms